Interleukin-17A blockade with secukinumab results in decreased neutrophil infiltration in psoriasis: minimally-invasive measurement by tape stripping by Loesche, Christian et al.
  
Interleukin-17A blockade with secukinumab results in decreased neutrophil infiltration in psoriasis: minimally-invasive measurement by tape strip-
ping. © 2016 Christian Loesche, et al. This is an Open Access article distributed under the terms of the Creative Commons Attribu-
tion-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), permitting all non-commercial use, distribution, and 
reproduction in any medium, provided the original work is properly cited.  
1 
RESEARCH ARTICLE 
Interleukin-17A blockade with secukinumab results in 
decreased neutrophil infiltration in psoriasis:  
minimally-invasive measurement by tape stripping 
Christian Loesche1§, Frank Kolbinger1§, Marie-Anne Valentin1, Philip Jarvis1, Melanie Ceci1,  
Grazyna Wieczorek1, Edward Khokhlovich1, Irina Koroleva1, Gerard Bruin1, Frank Sinner2,3,  
Birgit Aigner4 and Dhavalkumar D Patel1* 
1 Novartis Institutes of BioMedical Research, Basel, Switzerland 
2 HEALTH — Institute for Biomedicine and Health Sciences, Joanneum Research Forschungsgesellschaft m.b.H., Graz, 
Austria 
3 Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University Graz, Graz, Austria 
4 Department of Dermatology and Venerology, Medical University of Graz, Graz, Austria 
 
 
Abstract: Psoriasis is a well characterized interleukin (IL)-17A-driven skin disease with neutrophil infiltration and epi-
dermal hyperkeratosis. Several biomarkers, most prominently β-defensin-2 (BD-2), have been identified using local and 
systemic invasive measurements as responsive markers of IL-17A-driven skin pathology. We sought to determine 
whether measurements of epidermal proteins by tape stripping could offer a minimally-invasive method to assess treat-
ment responses. We compared the expression of 170 proteins in the epidermis (tape stripping) and dermis (open flow 
microperfusion) of 8 psoriatic subjects before and after administration of a single dose of subcutaneous (s.c.) anti- 
IL-17A mAb secukinumab. Proteomic analyses of tape strips revealed a >3-fold decrease in 32 epidermal and inflam-
matory cell proteins in response to secukinumab. The epidermal proteins with the largest (>10-fold) decreases were: 
matrix metalloproteinase-8 (MMP-8, 15.68-fold, p<0.05); myeloperoxidase (MPO, 14.72-fold, p<0.005); IL-8 
(11.93-fold, p<0.05); MMP-9 (10.81-fold, p<0.005); and IL-1β (10.35-fold, p<0.05). For these proteins, greater-fold 
protein changes were detected in the epidermis compared to dermis. Immunohistochemical analysis confirmed that neu-
trophils are the predominant cell type in psoriatic skin lesions that express MPO, MMP-8 and MMP-9, and that secuki-
numab treatment dramatically decreases neutrophil accumulation. Thus, tape stripping may be used to assess epidermal 
neutrophils, and protein biomarker responses to anti-IL-17A therapy in psoriasis. 
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Introduction 
laque psoriasis is a chronic inflammatory skin 
disorder characterized by infiltration of activat-
ed T lymphocytes, neutrophils, mast cells, and  
dendritic cells leading to epidermal keratinocyte  
hyperproliferation[1,2] affecting approximately 2%–3% 
of the general population[3]. Psoriasis treatment has 
recently been revolutionized with the introduction of 
interleukin (IL)-17A targeted therapies[4] achieving  P 
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rapid and lasting significant decrease in psoriatic pla-
ques (dramatic response in psoriasis area severity in-
dex [PASI] reduction). Much has been known about 
psoriasis pathogenesis and IL-17A biology by study-
ing gene and protein expression in skin biopsies be-
fore and after IL-17A-targeted therapies[5-9], including 
a prominent role of neutrophils in both processes[10]. 
These studies have identified β-defensin-2 (BD-2) 
encoded by the gene DEFB4A, as a biomarker of  
anti-IL-17A response in psoriasis. However, BD-2 
measurement has only been validated by invasive me-
thods such as skin biopsy and blood sampling, and 
most recently by minimal-invasive open flow micro-
perfusion (OFM) to measure proteins in dermal inters-
titial fluid (dISF)[6]. 
We sought to determine if therapeutic responses in 
psoriasis could be measured in a minimally-invasive 
manner by measuring epidermal proteins in the upper 
stratum corneum by skin tape stripping, and if ad-
ditional insights into psoriasis pathogenesis could be 
gained by comparing proteins in dermal and epidermal 
skin compartments. In this study, we examined 170 
proteins in the epidermis of eight psoriatic subjects be-
fore and 2 weeks after a single dose of the fully hu-
man, IL-17A-selective monoclonal antibody secuki-
numab (300 mg subcutaneous [s.c.]), and identified 
that neutrophil proteins were abundant and easily de-
tectable in psoriasis epidermis, and that they rapidly 
and strongly decreased after secukinumab treatment. 
While neutrophil protein changes were detectable in 
dISF, they were more readily and robustly detected in 
the epidermis. In contrast, BD-2 changes were larger 
in dISF than in the epidermis. Our findings shed new 
insights into the inflammatory pathways active in spe-
cific layers of psoriatic skin and reveal the proximal 
impact of IL-17A blockade on these pathways. 
Materials and Methods 
Study Design and Objectives 
This study was conducted as a part of a larger, pre-
viously reported single-center, open-label exploratory 
study (ClinicalTrials.gov identifier NCT01539213); the 
details of which have been previously described[6,11]. 
Specific to this study, eight subjects with moderate to 
severe psoriasis plaques who received a single 300 mg 
s.c. injection of secukinumab on study day 1 also  
underwent epidermal sampling by tape stripping be-
fore secukinumab treatment (Day 1) and on study day 
15 (D15, 14 days after secukinumab treatment). OFM 
was used to sample the dISF. 
Ethics 
The NCT01539213 study was carried out at the Clin-
ical Research Center of the Medical University in 
Graz, Austria, after being approved by the ethics 
committee and the Austrian Agency for Health and 
Food Safety (AGES). It was conducted according to 
the principles of Good Clinical Practice (GCP) and the 
Declaration of Helsinki. Written informed consent was 
obtained from each subject prior to any study specific 
procedures.  
In addition, skin biopsies from patients with psoria-
sis sampled in a previous multicenter trial NCT-
00805480, conducted after the approval of ethics com-
mittees and health authority, have been analyzed.  
Tape Stripping and Protein Measurement 
At baseline (Day 1, D1) and Day 15 (D15), 10 con-
secutive skin tape strip samples were collected after 
ethanol cleaning (CuDerm; D-Squame Standard Sam-
pling Discs; 22mm diameter; catalogue number D100) 
on skin from a representative psoriatic lesion in oth-
erwise healthy subjects. Proteins from skin tape strips 
were extracted for 2h at 4°C in 0.5 mL of assay buffer 
(50 mM Tris/HCl, 150 mM NaCl, 0.05% (v/v) 
CHAPS; adjusted to pH 7.6). 
With the exception of IL-17A, the chemilumines-
cent multiplex enzyme immunoassay platform from 
Aushon BioSystems (Billerica, MA, USA) was used 
to profile and quantify the levels of 170 proteins dis-
tributed over 43 panels as previously described[6]. Free 
IL-17A was quantified using microparticle-based flu-
orescent sandwich immunoassays based on Erenna 
technology validated in human serum (Singulex® IL- 
17A Human Immunoassay kit, Cat No.: 03-0017- 05). 
Free IL-17A levels in normal skin using tape strips 
were determined in healthy subjects (Novartis internal 
process). The lower limit of quantification (LOQ) for 
IL-17A was 0.096pg/mL. For comparison, dISF was 
sampled using OFM as previously described[11].  
Immunohistochemistry 
Three micrometer thick paraffin tissue sections from 
human skin biopsies were stained by immunohisto-
chemistry using Ventana Discovery XT stainer (Roche 
Diagnostics, Switzerland) and following primary an-
tibodies: rabbit anti-MPO, marker of neutrophils (po-
lyclonal, Dako, Denmark), rabbit anti-human MMP-8 
(clone EP1252Y, Abcam, UK), and rabbit anti-human 
MMP-9 (clone EP1254, Abcam, UK). Negative con-
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trol staining was performed with matched concentra-
tions of either mouse, rabbit, and goat isotype controls 
(MAB002, R&D Systems, UK, ab172730 and ab 27478, 
Abcam, UK and AB-108-C, R&D Systems, UK) in-
stead of the primary antibodies. 
Statistical Analysis and Hierarchical Clustering 
The PASI changes from baseline were analyzed using 
the Wilcoxon rank sum test as the number of subjects is 
small and the PASI clinical scale is ordinal and not linear. 
Serum and tape strip data from each subject was 
summarized using log (baseline/D15) or log fold de-
creases. Summary statistics on the log fold decrease 
scale have been back transformed to the fold change 
(increase or decrease) dependent on whether the log 
fold change summary statistics is positive or negative. 
If log (fold decrease) is negative, then we have a fold 
decrease and if log (fold decrease) is positive then we 
have a fold increase. Fold increases are usually    
understood but fold decreases can be confusing. For 
example, a sevenfold decrease from baseline indicates 
that the D15 values were 1/7 of the baseline value. 
The logfold decreases were analyzed using the Wil-
coxon rank sum test. 
All concentrations below LOQ were imputed as 
LOQ. One serum BD-2 concentration was above the 
upper LOQ and this was imputed as the upper LOQ. If 
concentrations were below LOQ at both BL and D15 
then that subject was excluded from the analysis. This 
approach for handling below LOQ or above the upper 
limit of quantification is conservative and produces 
the minimum log fold decreases. 
All tests were performed one-sided, either looking 
for a reduction from baseline which was the case for 
PASI or log fold decreases from baseline. No adjust-
ment was made for multiple testing. If one-sided    
p-values are less than 0.05, then they would be consi-
dered statistically significant decreases or log fold 
decreases from baseline. All analysis was performed 
using SAS version 9.3. 
The hierarchical clustering of the protein data and 
resulting heatmap and dendrogram graphic were gen-
erated using the “gplots” package of the R statistical 
platform (R version 3.2.2 and gplots version 2.17.0). 
Results 
Differential Protein Changes in Epidermis and  
Dermis After Anti-IL-17A Treatment 
We have previously reported that serum and dISF 
BD-2 protein levels are robust biomarkers of IL-17A 
driven skin pathology[6]. Both of these fluids require 
invasive sampling methods, and we sought to deter-
mine if non-invasive tissue sampling of the epidermis 
would be a reliable method to measure anti-IL-17A 
response at a molecular level. We sampled the upper 
stratum corneum of the epidermis before and 2 weeks 
after secukinumab treatment by tape stripping (Figure 
1), and measured 170 proteins using the same multip-
lexed chemiluminescent assay system as with dISF. In 
comparing the protein changes in epidermis vs. dermis, 
many differences were notable, including the levels of 
many proteins changed more dramatically in the epi-
dermis vs. the dermis (Figure 2). Using a 3-fold 
change from baseline as a threshold, 32 proteins were 
shown to be down-regulated in the epidermis (Table 1)  
 
 
 
Figure 1. Schematic representation of skin sampling methods used. Diagram showing the three structural layers of the skin: epider-
mis, dermis, and subcutaneous fatty tissue as well as blood vessels, hair follicles, sebaceous and sweat glands within the different 
layers of the skin. Compartments captured by tape stripping (red circle) and OFM (yellow arrows) are depicted on top. By courtesy of 
Encyclopaedia Britannica, Inc., copyright 2010; adapted with permission. 
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Figure 2. Proteomic analysis of different skin layers after IL-17A blockade reveal early changes in the epidermal compartment. 
Heatmap of 83 proteins with at least a 1.5 fold change (FC) at D15 compared to baseline in both, the epidermis and dermis, of psoria-
tic subjects treated at D1 with secukinumab. Epidermal tape strip samples and dISF samples were taken from lesional skin. Hierar-
chical clustering was performed on the fold-change of protein concentration to show changes in patterns of expression of related 
proteins in different compartments at two time points. Blue represents down-regulation from baseline and red indicates up-regulation. 
 
Table 1. Proteins with the greatest fold reduction (<−3.00) in the epidermis in comparison to the dermis of subjects with psoriasis 
after treatment with a single dose of secukinumab 
Protein Epidermis (tape strip) Dermis (dISF) Protein Epidermis (tape strip) Dermis (dISF) 
MMP-8 –15.68 –3.42 Thrombomodulin –4.30 –1.97 
MPO –14.72 –3.20 IL-12p40 –4.06 –1.47 
IL-8 –11.93 –16.03 α2–Macroglobulin –4.05 ND 
MMP-9 –10.81 –2.22 Acrp30 –4.01 2.72 
IL-1β –10.35 –5.47 PEDF –3.84 1.15 
MMP-1 –7.90 –15.19 ApoB100 –3.82 1.55 
GRO-α –7.29 –3.13 IGFBP2 –3.76 1.42 
IL-6 –6.92 –1.35 RBP4 –3.62 ND 
GRO-γ –6.28 –2.20 Fibrinogen –3.51 1.69 
MIF –5.57 1.31 VEGF –3.49 ND 
MIP-1β –5.18 –1.32 IL-17 –3.48 ND 
TNF-RI –4.86 –1.50 Epiregulin –3.42 –1.46 
Amphiregulin –4.69 –4.42 TGF-α –3.12 –2.25 
E–cadherin –4.59 –2.08 gp130 –3.11 1.82 
ProteinC –4.36 2.21 EGFR –3.07 1.03 
BD-2 –4.31 –32.20 IL-18 –3.00 1.04 
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compared with 8 in the dISF. While levels of BD-2, an 
antimicrobial peptide known to be a good IL-17A 
pathway marker, did decrease in the epidermis by 
4.3-fold at D15 (p<0.05, Figure 3) in parallel to im-
provements of disease activity (Figure 3), the change 
was not as high as in the dISF (32.2-fold), where BD-2 
was the protein with the highest fold-change (Table 1)[6]. 
Other proteins showed larger changes in the epidermis. 
IL-17A in tape strips from psoriasis subjects was not 
at levels high enough for detection by the Aushon 
system, but they were high enough to be detected us-
ing the Singulex system, with low but detectable le-
vels in all 8 psoriasis subjects before secukinumab, 
and undetectable levels in healthy volunteers (Figure 3). 
IL-17A Blockade Down-regulates Leukocyte Pro-
teases, Chemoattractants and Markers of Inflam-
mation 
The four proteins with the greatest-fold change in the 
epidermis by tape stripping were MMP-8, MPO, IL-8 
(CXCL8), and MMP-9 (Table 1 and Figure 4). In con-
trast, all of the proteins except IL-8 (which was not 
evaluable due to missing data) had much lower levels 
of change in the dISF, suggesting compartmental dif-
ferences in pathophysiology. To better understand the 
differences and define the source of these proteins, we 
performed immunohistochemistry on skin biopsies 
obtained before and 2 weeks after secukinumab therapy.  
 
 
 
 
Figure 3. Baseline epidermal protein levels of BD-2 decline rapidly in parallel to disease activity (PASI) upon secukinumab treat-
ment.(Upper panel) baseline human IL-17A levels in tape strip samples of psoriasis lesional and healthy volunteer skin; data below 
LOQ are shown as open symbols; (Lower panel, left) human BD-2 levels in tape strip samples of psoriasis lesional skin before and 
14 days after a single dose of secukinumab; (Lower panel, left) PASI scores before and 14 days after a single dose of secukinumab. 
Data for all 8 psoriasis patients are shown. Inserts show 25th and 75th percentiles, and vertical lines depict minimum and maximum 
values; the horizontal line depicts the Median value. Statistical significance was calculated using the Wilcoxon rank sum test 
(one-sided). Values below LOQ were included as LOQ. 
 
 
 
Figure 4. Leukocyte proteases and neutrophil-associated proteins are significantly reduced in the epidermis following secukinumab 
treatment. Protein levels in tape strip samples of psoriasis lesional skin before and 14 days after a single dose of secukinumab. Data 
for all 8 psoriasis patients are shown. Inserts show 25th and 75th percentiles and vertical lines depict minimum and maximum values; 
the horizontal line depicts the Median value. Statistical significance was calculated using the Wilcoxon rank sum test (one-sided). 
Values below LOQ were included as LOQ. 
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In the epidermis, the expression of MMP-8/MPO/ 
MMP-9 proteins was most abundant in Munro’s abs-
cesses filled with neutrophils, with lesser but evident 
neutrophil infiltration and MMP-8/MPO/MMP-9 ex-
pression in the dermis (Figure 5). Not only neutrophil 
numbers were reduced and neutrophil-produced pro-
teins down-regulated after secukinumab, but also pro-
tein levels of neutrophil-attracting chemokines other 
than IL-8, including CXCL1 (GRO-α), CXCL3 
(GRO- γ), and CXCL7 (NAP2) were decreased in the 
epidermis after the treatment (Table 1 and data not 
shown). While neutrophil-associated proteins repre-
sented the majority of chemo-attractants down-regu-
lated, IL-17A blockade also strongly down-regulated 
MIF[12,13], MIP-1α (CCL3), and MIP-1β (CCL4)[14,15], 
chemokines that may be involved in attracting and 
activating Th17, dendritic cells, and macrophages in 
lesional skin. Secukinumab also modulated the ex-
pression of the pro-inflammatory cytokines IL-1β, 
IL-6, IL-12p40, and IL-18 (Figure 6). 
IL-17A Blockade Results in Downregulation of 
Markers of Keratinocyte Proliferation  
Examination of the numerous changes in expression 
of proteins in the dermis and epidermis prompted us to 
examine whether specific pathways were strongly 
represented in these profiles. At the protein level, 
members of the epidermal growth factor (EGF)-family 
of autocrine keratinocyte growth factors, such as  
amphiregulin, epiregulin, and transforming growth 
factor alpha (TGF-α) were down-regulated, particu-
larly within the epidermis after administration of se-
cukinumab, suggesting that these ligands were driving 
keratinocyte hyperproliferation (Figure 7). In contrast, 
protein levels of EGF were unchanged or changed 
only slightly over time. 
 
 
Figure 5. Histopathology and immunohistochemistry of skin biopsies 
at baseline and on D15 after treatment with secukinumab. Left panel: 
representative example of skin biopsy with characteristic psoriatic 
pathology of acanthosis, parakeratosis, presence of Munro’s abscesses 
(MPO-positive), and dermal inflammatory infiltrates. Positive im-
mune-staining for MMP-8 and MMP-9 was found predominantly in 
neutrophils including Munro’s abscesses. Right panel: two weeks after 
treatment with a single dose of 10 mg secukinumab i.v., normalization 
of skin pathology, absence of Munro’s abscesses, and a marked reduc-
tion of dermal inflammatory infiltrates was observed. No MMP-8 and 
MMP-9 staining was observed on D15. Scale bars represent 400 μm 
(H&E) and 100 μm (IHC images). 
Discussion 
In this study, we wanted to explore a non-invasive 
method, using easy to handle and commercially 
available tape strips, to detect relevant disease markers 
and assess anti-IL-17A treatment responses in the ep-
idermis on a molecular basis and to compare these 
effects to dermal changes. Previously, tape stripping 
has been employed to detect proteolytic activities[16,17], 
 
 
Figure 6. IL-17A inhibition leads to reduction of pro-inflammatory cytokines in the epidermis of psoriasis patients. Cytokine protein levels in tape 
strip samples of psoriasis lesional skin before and 14 days after a single dose of secukinumab. Data for all 8 psoriasis patients are shown. Inserts show 
25th and 75th percentiles and vertical lines depict minimum and maximum values; the horizontal line depicts the median value. Statistical significance 
was calculated using the Wilcoxon rank sum test (one-sided). Values below LOQ were included as LOQ. NS= not significant (p>0.05). 
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Figure 7. Reduction of keratinocyte growth factors in the epidermis of psoriasis patients upon secukinumab treatment. Protein levels 
of members of the EGF-family of growth factors in tape strip samples of psoriasis lesional skin before and 14 days after a single dose 
of secukinumab. Data for all 8 psoriasis patients are shown. Inserts show 25th and 75th percentiles and vertical lines depict minimum 
and maximum values; the horizontal line depicts the median value. Statistical significance was calculated using the Wilcoxon rank 
sum test (one-sided). Values below LOQ were included as LOQ. NS=not significant (p>0.05). 
An early effect on keratinocyte proliferation by IL-17A blockade was confirmed by a reduction of Ki67 and keratin 16, direct and 
indirect markers of keratinocyte proliferation, by IHC[8,10] and by gene expression analysis of biopsy samples[10] (Data not shown). 
 
disrupt the skin barrier before immunization[18], and to 
evaluate drug concentrations in skin[19,20]. To the best 
of our knowledge, de Jongh (2008) was one of the 
first to quantify cytokines (IL-1α) in diseased lesional 
stratum corneum from atopic dermatitis patients using 
this non-invasive technique. More recently, as protein 
detection methods have improved, tape stripping has 
been applied to measure stratum corneum concentra-
tions of single proteins, primarily in atopic dermatitis. 
Indeed, stratum corneumBD-2, IL-8, thymus and ac-
tivation-regulated chemokine (TARC), and thymic 
stromal lymphoprotein (TSLP) have been individually 
measured by tape stripping and correlated with disease 
activity in atopic dermatitis[21–24]. Stratum corneum 
protein levels can be influenced by genetic polymor-
phisms, suggesting that they are responsive and rele-
vant to biological influences[25–28]. Undeniably, res-
ponses to drug therapy for example doxycycline in ro-
sacea may also be monitorable[29]. In this study, we 
were able to measure and quantify protein levels of a 
large number of proteins simultaneously in a multiple-
xed format from tape strips using a highly sensitive 
chemiluminescent multiplex enzyme immunoassay. 
While some proteins like IL-17A were difficult to det-
ect with this system, they were detectable with suffi-
ciently sensitive assays like Singulex, tested indivi-
dually. 
We have recently shown that BD-2, measured in 
either serum or dISF, was a robust biomarker of pso-
riasis disease activity that responds rapidly to IL- 
17A blockade with secukinumab[6]. We also suggested 
that serum BD-2 may be a surrogate for IL-17A me-
diated skin disease activity that could be used to mon-
itor responses to anti-IL-17A targeted therapies. Ho-
wever, this would require invasive monitoring by ve-
nipuncture. We showed here that BD-2 can also be 
monitored by tape stripping. However, the fold-chan-
ge in stratum corneum BD-2 levels was smaller than 
in dISF, but similar to that in serumat D15[6]. Due to 
the turnover of the epidermal layers, we may hypo-
thesize that it may take longer to detect bigger cha-
nges in the epidermis than in serum. However, BD-2 
measurement by tape stripping may be valuable to 
monitor anti-IL-17A responses in psoriasis, as we did 
not detect significant side effects of the technique in 
our study. We have shown that therapeutically relevant 
dermal concentrations of secukinumab are detected in 
these 8 psoriasis patients at D8 and D15[11] and thus, a 
direct local effect on dermis and epidermis may be 
possible. While BD-2 may not be a unique marker of 
response to anti-IL-17A therapies, as BD-2 was quali-
tatively shown to be reduced by immunohistochemical 
staining following anti-TNFα treatment using etaner-
cept[30], our data indicated that BD-2 measurements in 
serum[6] or by tape stripping may be useful in moni-
toring residual disease activity or early responses to 
different therapies in psoriasis. However, an early 
complete clearance of skin lesions remains the most 
important and clinically relevant marker for response 
to therapy. Whether BD-2 may also be useful in   
predicting response to therapy or strength of therapeu-
tic response (e.g., PASI90) remains an open question 
and would require larger prospective clinical studies. 
The proteins with the highest fold-change in stratum 
corneum in response to secukinumab were MMP-8, 
MPO, IL-8, MMP-9, and IL-1β. MMP-8, MPO, and 
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MMP-9 were consistently detectable at high levels in 
psoriasis stratum corneum while the cytokines IL-1β 
and IL-8 were present at slightly lower but consis-
tently detectable levels. All five proteins responded 
well to IL-17A blockade in a statistically significant 
manner. Immunohistochemistry showed that the pro-
teins were expressed primarily by neutrophils. Since 
MPO is a specific marker of neutrophils, and MMP-8 
and MMP-9 are neutrophil-associated proteases, their 
localization to neutrophils was not surprising. Munro 
originally identified the association between epider-
mal neutrophil microabscesses and psoriasis[31], and 
others have highlighted their role in IL-17A respo-
nses[10,32]. These findings have led to a resurgence in 
the interest of neutrophils in psoriasis. Our study also 
highlights the importance of neutrophils to psoriasis 
pathogenesis and response to IL-17A based therapies.   
Another novel finding of this study was the obser-
vation that protein levels of three EGF-family ligands 
(amphiregulin, epiregulin, and TGF-α) were rapidly 
down-regulated upon IL-17A inhibition by secukinu-
mab. These findings are consistent with earlier tran-
scriptional data where amphiregulin, epiregulin, and 
TGF-α mRNA were found to be overexpressed in pso-
riatic epidermis and confined to the spinous layer but 
not the basal layer of psoriatic skin[33,34]. These three 
proteins are produced and secreted by human kerati-
nocytes and act as autocrine growth factors[35]. Based 
on these data, we hypothesize that amphiregulin, epi-
regulin, and TGF-α may be important in driving the 
epidermal hyperproliferation seen in psoriasis. Down- 
regulation of amphiregulin has been demonstrated 
to be linked to epidermal remodeling and keratinocyte 
migration with shedding of membrane-bound E-cadh-
erin being increased in amphiregulin transgenic mice 
displaying psoriasis-like skin alterations[36]. Interes-
tingly, we found that soluble E-cadherin, which is be-
lieved to reduce keratinocyte cell-cell adhesion and th-
ereby facilitate increased keratinocyte motility and ne-
utrophil migration in the highly proliferative lesional 
psoriatic skin, was down-regulated in psoriatic lesions. 
Conclusion 
In summary, this exploratory study has shown that 
minimally invasive tape stripping provides a useful 
way to assess disease pathomechanisms as well as 
response to a targeted therapy at the protein level di-
rectly in diseased skin. While providing further details 
on mechanisms of IL-17A targeting therapies such as 
secukinumab in psoriasis, tape stripping combined 
with proteomic analysis should also be useful in as-
sessing disease pathomechanisms and activated path-
ways in other skin diseases. 
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